Christoph Maintz

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

Andrea Kaifie, Martin Kirschner, Dominik Wolf‎ et al. · Journal of Hematology & Oncology · 2016 · 184 citations · Full text

Medicine, Hematology, Internal Medicine +17

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker et al. · Leukemia · 2020 · 92 citations · Full text

Life Sciences, Hematology, Oncology +16

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Arnd Nusch et al. · Lung Cancer · 2020 · 90 citations · Full text

Medicine, Molecular Medicine, Oncology +13

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders

Edgar Jost, Nicole do Ó, Edgar Dahl et al. · Leukemia · 2007 · 83 citations

Life Sciences, Genetics, Molecular Biology +16